RnRMarketResearch.com adds “Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H2 2014“ report to its research database.
The report “Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H2 2014“ provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies discussed in this research include AbbVie Inc., Amarantus Bioscience Holdings, Inc., Avineuro Pharmaceuticals, Inc., BIOPROJET SCR, CoMentis, Inc., Eli Lilly and Company, FORUM Pharmaceuticals Inc., H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Iproteos S.L., Merck & Co., Inc., Mithridion, Inc., Mnemosyne Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Saniona AB, Siena Biotech S.p.A., SK Biopharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Limited, Upsher-Smith Laboratories, Inc.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248284 .
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope of Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H2 2014 covers: snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS); reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type.
Reasons to buy